Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2025

Nov 5, 2025

33422_dirs_2025-11-05_c41069c6-3e1d-48ae-b796-3ee92bb2e169.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2025-11-03

Reporting Person: CALLICUTT JACK W (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-03 Common Stock M 1300 $1.98 Acquired 8914 Direct
2025-11-03 Common Stock S 1300 $6.01 Disposed 7614 Direct
2025-11-03 Common Stock M 1260 $1.11 Acquired 8874 Direct
2025-11-03 Common Stock S 1260 $6.01 Disposed 7614 Direct
2025-11-03 Common Stock M 1250 $1.72 Acquired 8864 Direct
2025-11-03 Commno stock S 1250 $6.01 Disposed 7614 Direct
2025-11-04 Common stock M 8914 $1.98 Acquired 16528 Direct
2025-11-04 Common stock S 8914 $6.07 Disposed 7614 Direct
2025-11-04 Common stock M 8974 $1.11 Acquired 16588 Direct
2025-11-04 Common stock S 8974 $6.07 Disposed 7614 Direct
2025-11-04 Common stock M 10741 $1.72 Acquired 18355 Direct
2025-11-04 Common stock S 10741 $6.07 Disposed 7614 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-11-03 Stock option (right to buy) $1.98 M 1300 Disposed 2032-01-24 Common Stock (1300) Direct
2025-11-03 Stock option (right to buy) $1.11 M 1260 Disposed 2033-01-26 Common Stock (1260) Direct
2025-11-03 Stock option (right to buy) $1.72 M 1250 Disposed 2034-01-22 Comm stock (1250) Direct
2025-11-04 Stock option (right to buy) $1.98 M 8914 Disposed 2032-01-24 Common stock (8914) Direct
2025-11-04 Stock option (right to buy) $1.11 M 8974 Disposed 2034-01-26 Common stock (8974) Direct
2025-11-04 Stock option (right to buy) $1.72 M 10741 Disposed 2034-01-22 Common stock (10741) Direct

Footnotes

F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

F4: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

F5: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.

F6: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.